What is HC Wainwright’s Estimate for Immunome Q1 Earnings?

Immunome, Inc. (NASDAQ:IMNM) – Investment analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of Immunome in a research report issued on Tuesday, November 10th. HC Wainwright analyst A. Maldonado anticipates that the company will earn ($0.72) per share for the quarter. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.48) per share. HC Wainwright also issued estimates for Immunome’s Q2 2027 earnings at ($0.70) EPS, Q3 2027 earnings at ($0.69) EPS and Q4 2027 earnings at ($0.60) EPS.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.14).

IMNM has been the subject of several other reports. Wall Street Zen lowered shares of Immunome from a “sell” rating to a “strong sell” rating in a research report on Sunday, October 4th. William Blair assumed coverage on shares of Immunome in a research report on Friday, October 16th. They set an “outperform” rating on the stock. Truist Financial upped their price target on shares of Immunome from $37.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Stifel Nicolaus decreased their price target on shares of Immunome from $24.00 to $23.00 and set a “hold” rating for the company in a report on Tuesday. Finally, Alliance Global Partners started coverage on shares of Immunome in a report on Monday, September 21st. They set a “buy” rating and a $32.00 price objective on the stock. Fourteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $33.85.

Immunome Stock Performance

Shares of IMNM stock opened at $18.65 on Wednesday. Immunome has a fifty-two week low of $16.11 and a fifty-two week high of $30.06. The firm has a market capitalization of $2.12 billion, a price-to-earnings ratio of -7.06 and a beta of 2.68. The stock’s 50-day simple moving average is $21.15 and its 200-day simple moving average is $22.33.

Insider Buying and Selling at Immunome

In other news, insider Jack Higgins sold 13,200 shares of the business’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $25.32, for a total value of $334,224.00. Following the completion of the transaction, the insider owned 65,050 shares of the company’s stock, valued at $1,647,066. The trade was a 16.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 7.21% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Edgestream Partners L.P. acquired a new position in Immunome in the third quarter valued at approximately $2,923,000. Russell Investments Group Ltd. increased its holdings in shares of Immunome by 213.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 93,946 shares of the company’s stock valued at $2,021,000 after purchasing an additional 63,985 shares in the last quarter. Three Bridge Wealth Advisors LLC purchased a new position in shares of Immunome during the 3rd quarter valued at approximately $164,000. Alps Advisors Inc. lifted its stake in shares of Immunome by 31.5% in the 3rd quarter. Alps Advisors Inc. now owns 150,502 shares of the company’s stock valued at $3,237,000 after purchasing an additional 36,062 shares during the period. Finally, Sterling Capital Management LLC lifted its stake in shares of Immunome by 840.0% in the 3rd quarter. Sterling Capital Management LLC now owns 3,478 shares of the company’s stock valued at $75,000 after purchasing an additional 3,108 shares during the period. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Immunome

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and forecast quarterly losses of $0.72, $0.70, $0.69 and $0.60 per share for Q1–Q4 2027, respectively. The forecasts indicate continued losses, but the Buy rating is supportive.
• Positive Sentiment: Piper Sandler maintained an Overweight rating and a $30 price target, despite lowering it from $33. Piper Sandler ratings
• Neutral Sentiment: Immunome released its third-quarter results and a business update; the supplied coverage does not detail the update’s contents. Immunome third-quarter results and business update
• Negative Sentiment: Immunome reported a third-quarter loss of $0.76 per share, missing the consensus estimate of a $0.62 loss by $0.14 per share. Immunome earnings press release
• Negative Sentiment: Stifel Nicolaus lowered its price target from $24 to $23 and kept a Hold rating, signaling less upside in its view. Stifel Nicolaus ratings

Immunome Company Profile

Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need. The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.